In this article, we will take a look at the 10 Set-It-and-Forget-It Stocks to Buy Right Now.
A peace pact agreed upon by the United States and Iran on June 18 helped ease concerns about inflation that had been weighing on markets. The two sides declared a temporary agreement to maintain the ceasefire and reopen the Strait of Hormuz. The rebound occurred despite the Federal Reserve’s shift to a more hawkish stance, as inflation remained high and the labor market remained stable throughout the dispute with Iran.
Labor Department data on June 18 showed initial unemployment claims were a bit higher than expected but had cooled over the prior week. In contrast to their March estimates, nine Fed members now anticipate at least one rate hike before the year ends. Additionally, markets noted that Chair Kevin Warsh’s initial policy statement focused on achieving “price stability” but made no mention of maximum employment.
In response to Warsh’s remarks, SignatureFD Chief Investment Officer Tony Welch told Reuters that “markets got spooked by Warsh yesterday essentially promising to contain inflation.” That said, he added that the data remains supportive regardless of the Fed becoming increasingly hawkish.
Our Methodology
To identify the 10 set-it-and-forget-it stocks to buy, we screened for large-cap stocks (market cap above $10 billion) with a positive EPS over the past five years and an ROE of more than 15%. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Deere & Company (NYSE:DE)
Deere & Company ranks among the best set-it-and-forget-it stocks to buy right now. On May 26, RBC Capital increased its price target for Deere & Company to $752 from $736, retaining an Outperform rating on the company’s shares. The firm referenced Deere’s second-quarter earnings, which outperformed forecasts despite the absence of an IEEPA tariff return.
Deere & Company earned $6.55 per share, above the estimates of $5.70, while revenue came in at $13.37 billion, exceeding the expected $11.56 billion.
RBC highlighted that Deere’s fiscal 2026 outlook remained steady, given that the tariff return advantage was offset by a number of factors, including a downturn in South America. According to the firm, Deere continues to perform effectively in a hard climate.
Meanwhile, Freedom Broker increased its price target for Deere & Company to $590 from $570 with a Hold rating. According to the firm, 2026 marks the low point of the major agricultural equipment cycle. Freedom also emphasized that Deere’s diverse portfolio is producing stronger intrinsic profitability at the cycle’s low stage when compared to past cycles.
Deere & Company is an American company that manufactures agricultural, heavy, and forestry machinery, diesel engines, heavy-equipment drivetrains, and lawn-care equipment. The company also provides financial services and engages in other business operations.
9. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Intuitive Surgical, Inc. (NASDAQ:ISRG) ranks among the best set-it-and-forget-it stocks to buy right now. On June 2, Piper Sandler restated its Overweight rating and $580 target on Intuitive Surgical, Inc.. The firm’s recent field check with the head of robotics at a prominent U.S. healthcare institution confirmed the firm’s positive opinion of the company. The hospital system has significant expertise with Intuitive Surgical’s da Vinci system, notably the DV5 model, as well as other robotic solutions.
The field check focused on issues regarding the long-term viability of US volume growth, third-party equipment reprocessing, and increasing competition.
Piper Sandler recognized many growth catalysts for Intuitive Surgical, Inc., such as the ambulatory surgery center possibility, DV5 cardiovascular treatments, and My Intuitive+. The firm claimed it is convinced the basic fundamentals of the company remain solid and that prevailing concerns are blown out of proportion.
In addition, Intuitive Surgical, Inc. recently announced upgrades to its da Vinci 5 robotic surgical system, which include improved Intuitive Telepresence and longer tool use, which is expected to be ready in June, subject to regulatory clearance.
Intuitive Surgical, Inc. engages in the development, manufacturing, and marketing of da Vinci surgical systems and the Ion endoluminal system.
8. Stryker Corporation (NYSE:SYK)
Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy right now. On June 5, Leerink reduced its price target for Stryker Corporation to $407 from $410 while keeping an Outperform rating on the company’s stock. The firm changed its SYK model in response to new 10-Q filings following the company’s first-quarter 2026 results.
The company fell short of analysts’ forecasts, reporting earnings per share of $2.60 vs an estimate of $2.98, with revenue of $6 billion coming below an expected $6.34 billion. Despite these challenges, Stryker Corporation has reiterated its 2026 projection.
The fiscal 2026 earnings per share projection fell by $0.01, reflecting management’s statement that a significant portion of the revenue deficit in the first quarter due to a cyberattack is expected to be recovered in the second half of the year. The firm’s EPS expectations for fiscal 2027 and fiscal 2028 were reduced by about 1% to reflect the impact of the most recent disclosures.
Leerink, however, stated that it still sees a solid risk/reward skew for Stryker Corporation and thinks the company is still among the better-positioned names in large-cap medical technology.
Founded in 1981, Stryker Corporation is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopedics, MedSurg, and Neurotechnology and Spine.
7. The TJX Companies, Inc. (NYSE:TJX)
The TJX Companies, Inc. (NYSE:TJX) ranks among the best set-it-and-forget-it stocks to buy right now. On June 9, UBS reaffirmed its Buy rating and $197 price target for The TJX Companies, Inc., citing data gathered from the 9th annual US Off-Price and Department Store Retailers Consumer Survey. According to the report, 71% of respondents believe T.J. Maxx provides excellent value for money in comparison to other department stores.
Based on the most recent poll wave, 78% of respondents cited T.J. Maxx’s wide assortment and products as an incentive to shop, a rise from 44% in Wave 8 and 37% in Wave 6. With 62% relevance, assortment breadth ranks as one of the most important decision-making factors.
Additionally, Truist Securities maintained a buy rating on The TJX Companies, Inc. on May 21 while increasing its price target from $175 to $190. The price target hike comes after TJX’s recent earnings report, which highlighted results that beat forecasts across a variety of metrics.
Instead of pointing to more general macroeconomic strength, Truist ascribed the outperformance to TJX’s competitive positioning and advantageous circumstances in the off-price retail industry.
The TJX Companies, Inc. is a well-known off-price clothing and home fashion retailer. Its store brands include T.J. Maxx, Marshalls, and HomeGoods, as well as international names such as T.K. Maxx and Winners.
6. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc.. The firm published a detailed review of the Sjogren’s syndrome therapeutic development environment in advance of Amgen’s CD40 ligand-directed fusion protein dazodalibep’s Phase III conclusion in the latter half of 2026.
Amgen Inc. is conducting research in two distinct Sjogren’s categories: moderate-to-severe symptoms-related burden with low systemic disease progression and moderate-to-severe systemic disease activity.
According to Piper Sandler, dazodalibep is a comparatively underappreciated part of Amgen’s growing immunology/inflammation pharmaceutical line.
In a similar vein, Morgan Stanley maintained its Overweight rating on Amgen Inc. while increasing its price objective to $340 from $332 on June 9. The firm pointed out that Amgen’s portfolio of cutting-edge medications is bolstered by the company’s recent acquisition of Horizon.
According to Morgan Stanley, the stock’s future depends on pipeline development, with a major focus on MariTide against obesity.
Amgen Inc. is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
5. Gilead Sciences Inc. (NASDAQ:GILD)
Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. on June 9, following the company’s clinical research findings.
Gilead Sciences Inc., in collaboration with Merck, revealed solid top-line results from the phase 3 ISLEND-1 and ISLEND-2 studies of weekly islatravir/lenacapavir for HIV medication. Additionally, the companies reported negative findings from the EVOKE-03 study comparing Trodelvy with Keytruda versus Keytruda monotherapy in patients with first-line PD-L1 non-small cell lung cancer.
Moreover, on June 8, RBC Capital reaffirmed its $122 Sector Perform rating for Gilead Sciences Inc.. The firm made remarks regarding the company’s position in the domain of in vivo CAR-T treatment.
The firm added that in vivo CAR-T represents a possible risk to a sector that is estimated to account for 10-15% of Gilead’s potential revenue. According to RBC Capital, Gilead Sciences Inc. has begun to build promising technology in the field with differentiating features and a wide approach that incorporates current experience.
Gilead Sciences Inc. is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.
4. ServiceNow Inc. (NYSE:NOW)
ServiceNow Inc. (NYSE:NOW) ranks among the best set-it-and-forget-it stocks to buy right now. Following a discussion with ServiceNow Inc. management, Oppenheimer reiterated its Outperform rating and $130 price target for ServiceNow on June 10. The conversation left the firm slightly optimistic about ServiceNow’s second-half 2026 prospects and the likelihood of business reacceleration in the year to come.
The firm believes ServiceNow Inc. has strong fiscal year 2030 financial targets, with the company appearing to be on track for a 10%+ AI business by 2026, with a subscription revenue gross margin floor projection.
Furthermore, on June 4, Cognizant Technology announced the integration of its Neuro AI Trust platform with ServiceNow Inc., which will provide companies with comprehensive AI governance and monitoring tools across AI platforms.
The integration creates what the companies refer to as a unified ecosystem for handling AI governance across the AI lifecycle by combining ServiceNow’s AI Control Tower with Cognizant’s AI assurance platform.
ServiceNow Inc. provides cloud-based and AI-embedded end-to-end workflow automation solutions for enterprises. The company is located in Santa Clara, California, and was founded in June 2004 by Frederic B. Luddy.
3. Honeywell International Inc. (NASDAQ:HON)
Honeywell International Inc. (NASDAQ:HON) ranks among the best set-it-and-forget-it stocks to buy right now. Following the company’s investor day event, which featured panels, presentations, and meetings with the management team, Mizuho reaffirmed an Outperform rating on Honeywell International Inc. with a $240 price target on June 12. Notably, the company announced its three-year financial targets at the event, which include 4% to 6% organic growth and over 60 basis points in annual margin growth.
Mizuho observed that the investor day’s tone was optimistic and self-assured, emphasizing physical AI momentum, portfolio change, and a business strategy focused on developing and refining the existing base.
However, the firm stated that management must demonstrate increased development following weak performance in recent years, notably in the Industrial Automation and Process Automation & Technology segments. According to Mizuho, if the expected 3-4% like-for-like pricing impact is achieved over the coming three years, the base volume estimates appear cautious considering the low levels across several divisions.
Honeywell International Inc. operates across multiple business areas, including industrial automation, aerospace technologies, building automation, and energy and sustainable solutions. The company operates across Europe, the United States, and other international markets.
2. Salesforce Inc. (NYSE:CRM)
Salesforce Inc. (NYSE:CRM) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, TD Cowen reaffirmed its $240 price objective and Buy rating on Salesforce Inc.. The update came after the firm hosted an investor dinner with new IR Senior Director Lauren O’Brien and the Vice President of Investor Relations, Valmik Desai.
The discussion focused on shaping AI momentum in the first quarter and its effects for second-half growth acceleration, Agentforce’s market edge, and new implementation of FDEs, the transition to a headless framework, and Slack’s strategic significance.
Moreover, on that same day, CVS Health and Salesforce Inc. announced an extension of their collaboration to implement AI technology throughout call centers that cater to clinicians and members of CVS Health’s Aetna and CVS Caremark brands.
CVS Health will leverage Salesforce’s Agentforce Health platform to give real-time data to call center workers. The technology aims to enable call centers to resolve customer concerns in a single interaction when possible.
Salesforce Inc. is a global enterprise software company that provides customer relationship management (CRM) and cloud-based business applications across sales, service, marketing, commerce, and data analytics. Its Customer 360 platform, powered by data tools and trusted AI, enables organizations to unify customer data and drive personalized engagement.
1. PepsiCo, Inc. (NASDAQ:PEP)
PepsiCo, Inc. (NASDAQ:PEP) ranks among the best set-it-and-forget-it stocks to buy right now. On June 11, Bernstein SocGen Group began coverage of PepsiCo, Inc. with a Market Perform rating and a price objective of $143. The firm identified issues in the company’s snacking industry, pointing out that PepsiCo, Inc. endures the most challenging category condition across companies in its covered universe and is losing its market dominance.
In contrast, Pepsico’s international business remains strong and profitable, countering some of its North American problems. According to Bernstein, the market understands this edge quite well.
The firm anticipates 3% year-over-year earnings per share increase during the upcoming twelve months and the subsequent twelve months.
Moreover, Barclays analysts have highlighted that consumer products companies, such as PepsiCo, Inc., can manage rising input costs while preserving profit margins. This review comes as the SEC considers switching U.S. public corporations to semi-annual financial reporting.
One of the most well-known names in the world, PepsiCo, Inc., is an American multinational company involved in the food, snack, and beverage sectors.
